Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

被引：53

作者：

Nigro, Olga ^{[1
]}

Pinotti, Graziella ^{[1
]}

De Galitiis, Federica ^{[2
]}

Di Pietro, Francesca Romana ^{[2
,3
]}

Giusti, Raffaele ^{[3
]}

Filetti, Marco ^{[3
]}

Bersanelli, Melissa ^{[4
]}

Lazzarin, Alessandro ^{[4
]}

Bordi, Paola ^{[4
]}

Catino, Annamaria ^{[5
]}

Pizzutilo, Pamela ^{[5
]}

Galetta, Domenico ^{[5
]}

Marchetti, Paolo ^{[2
,6
]}

Botticelli, Andrea ^{[6
]}

Scagnoli, Simone ^{[6
]}

Russano, Marco ^{[7
]}

Santini, Daniele ^{[7
]}

Torniai, Mariangela ^{[8
]}

Berardi, Rossana ^{[8
]}

Ricciuti, Biagio ^{[9
]}

De Giglio, Andrea ^{[9
]}

Chiari, Rita ^{[10
]}

Russo, Alessandro ^{[11
]}

Adamo, Vincenzo ^{[11
]}

Tudini, Marianna ^{[12
]}

Silva, Rosa Rita ^{[12
]}

Bolzacchini, Elena ^{[13
]}

Giordano, Monica ^{[13
]}

Di Marino, Pietro ^{[14
]}

De Tursi, Michele ^{[15
]}

Rijavec, Erika ^{[16
]}

Ghidini, Michele ^{[16
]}

Vallini, Ilaria ^{[1
]}

Stucci, Luigia Stefania ^{[17
]}

Tucci, Marco ^{[17
,25
]}

Pala, Laura ^{[18
]}

Conforti, Fabio ^{[18
]}

Queirolo, Paola ^{[18
]}

Tanda, Enrica ^{[19
]}

Spagnolo, Francesco ^{[19
]}

Cecchi, Federica ^{[19
]}

Bracarda, Sergio ^{[20
]}

Macrini, Serena ^{[20
]}

Santoni, Matteo ^{[21
]}

Battelli, Nicola ^{[21
]}

Fargnoli, Maria Concetta ^{[22
,23
]}

Porzio, Giampiero ^{[22
,24
]}

Tuzi, Alessandro ^{[1
]}

Suter, Matteo Basilio ^{[1
]}

Ficorella, Corrado ^{[22
,24
]}

机构：

[1] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy

[2] IDI IRCCS, Oncol & Oncol Dermatol, Rome, Italy

[3] Azienda Osped Univ St Andrea, Med Oncol, Rome, Italy

[4] Azienda Osped Univ Parma, Med Oncol, Parma, Italy

[5] IRCCS Ist Tumori Giovanni Paolo II, Thorac Oncol Unit, Bari, Italy

[6] Univ Roma La Sapienza, Dipartimento Sci Med Chirurg & Med Traslaz, Rome, Italy

[7] Med Oncol, Campus Biomed, Rome, Italy

[8] Univ Politecn Marche, Clin Oncol, Azienda Osped Univ Osped Riuniti Umberto 1, GM Lancisi, Ancona, Italy

[9] Univ Perugia, Dept Surg & Biomed Sci, Perugia, Italy

[10] Osped Riuniti Padova Sud Madre Teresa Di Calcutta, Med Oncol, Monselice, Italy

[11] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[12] ASUR Marche, Area Vasta 2, Med Oncol, Fabriano, Italy

[13] Osped St Anna, ASST Lariana, Med Oncol, Como, Italy

[14] SS Annunziata Hosp, Clin Oncol Unit, Chieti, Italy

[15] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[16] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Med Oncol Unit, Milan, Italy

[17] Univ Bari, Med Oncol Unit, Dept Biomed Sci & Human Oncol, Bari, Italy

[18] IRCCS, European Inst Oncol, Div Med Oncol Melanoma Sarcoma & Rare Tumors, IEO, Milan, Italy

[19] Osped Policlin San Martino, IRCCS, Genoa, Italy

[20] Santa Maria Hosp, Dept Med Oncol, Terni, Italy

[21] Macerata Hosp, Dept Oncol, Macerata, Italy

[22] St Salvatore Hosp, Dept Dermatol, Laquila, Italy

[23] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[24] St Salvatore Hosp, Med Oncol, Laquila, Italy

[25] Tumori Inst Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 134卷

关键词：

Immunotherapy; Immune checkpoint; Nivolumab; Pembrolizumab; Atezolizumab; Immune-related adverse events; ELDERLY-PATIENTS; CANCER;

D O I：

10.1016/j.ejca.2020.04.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Data on spectrum and grade of immune-related adverse events (irAEs) in long-term responders to immune checkpoint inhibitors (ICIs) are lacking. Methods: We performed a retrospective multicenter study to characterized irAEs occurring after a 12-months minimum treatment period with PD-(L)1 ICIs in patients with advanced cancer. IrAEs were categorized into 'early' (<= 12 months) and 'late' (>12 months). Results: From September 2013 to October 2019, 436 consecutive patients were evaluated. Two hundred twenty-three experienced any grade early-irAEs (51.1%), whereas 132 experienced any grade late-irAEs (30.3%) (p < 0.0001). Among the latter, 29 (22%) experienced a recurrence of an early-irAEs, whereas 103 (78%) experienced de novo late-irAEs involving different system/organ. Among patients with late-irAEs, 21 experienced GIII/GIV irAEs (4.8%). Median time to onset of early-irAEs was 3.4 months (95% confidence interval [CI]: 2.8-4.2), whereas the median time to onset of late-irAEs was 16.6 months (95% CI: 15.8-17.6). Cumulative time-adjusted risk of disease progression according to both the early-irAEs (hazard ratio [HR] = 0.63 [95% CI: 0.30-1.29], p = 0.204) and late-irAEs occurrence revealed no statistically significant differences (HR = 0.75 [95% CI: 0.37-1.56], p = 0.452). In addition, the time-adjusted cumulative risk of death in accordance with both early-irAEs (HR = 0.79 [95% CI: 0.34-1.86], p = 0.598) and late-irAEs (HR = 0.92 [95% CI: 0.49-1.74], p = 0.811) did not show statistically significant differences. Conclusion: Although less frequent than early-irAEs, late-irAEs are quite common in long responders to PD-(L)1 ICIs and are different in terms of spectrum and grade. Time-adjusted analysis revealed that the cumulative risk of disease progression and death were not significantly reduced in patients who experienced late-irAEs. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：19 / 28

页数：10

共 50 条

[41] Pulmonary Immune-Related Adverse Events ofPD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
Ebinama, Ugochi
Sheshadri, Ajay
Anand, Kartik
Swaminathan, Iyer
JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (04) : 177 - 184
[42] Retrospective study of immune-related adverse events in NSCLC patients treated with PD-1 inhibitors
Otsubo, Aya
Ota, Takeshi
Okajima, Masaaki
Tanaka, Hiroshi
Ishida, Takashi
Iwashima, Akira
Watanabe, Satoshi
Sato, Kazuhiro
Matsumoto, Naoya
Miyabayashi, Takao
Terada, Masaki
Sato, Ko
Ishikawa, Daisuke
Tanabe, Yoshinari
Yoshizawa, Hirohisa
Kikuchi, Toshiaki
ANNALS OF ONCOLOGY, 2019, 30
[43] Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study
Zhang, J.
Gao, A.
Li, J.
Wang, S.
Sun, H.
Sun, Y.
Cheng, Q.
Wu, J.
Ge, Y.
Sun, Y.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S689 - S689
[44] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
Frey, Connor
Etminan, Mahyar
ANTIBODIES, 2024, 13 (03)
[45] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Liu, Jinhua
Chen, Zichao
Li, Yaqun
Zhao, Wenjie
Wu, JiBiao
Zhang, Zhen
FRONTIERS IN PHARMACOLOGY, 2021, 12
[46] PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
Song, Qingya
Yu, Zongliang
Lu, Wenping
Zhuo, Zhili
Chang, Lei
Mei, Heting
Cui, Yongjia
Zhang, Dongni
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
[47] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, Dongxu
Lin, Jianzhen
Yang, Xu
Long, Junyu
Bai, Yi
Yang, Xiaobo
Mao, Yilei
Sang, Xinting
Seery, Samuel
Zhao, Haitao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
[48] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Dongxu Wang
Jianzhen Lin
Xu Yang
Junyu Long
Yi Bai
Xiaobo Yang
Yilei Mao
Xinting Sang
Samuel Seery
Haitao Zhao
Journal of Hematology & Oncology, 12
[49] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, Mario
Indraccolo, Stefano
Zagonel, Vittorina
Lombardi, Giuseppe
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
[50] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
Maslanka, A.
Kitel, R.
Konopka, J.
Skalniak, L.
FEBS OPEN BIO, 2024, 14 : 329 - 330

← 1 2 3 4 5 →